DNA Electronics is a pioneer in genomic analysis, dedicated to applying our proven molecular diagnostic technology to bring real, life-saving benefits to patients. As the inventors of semiconductor sequencing (on-chip sequencing and analysis), we have created a new platform that is ideally suited to point-of-need diagnostics, by delivering actionable results direct from blood.
We call this Genalysis®.
Our first flagship product is a test that quickly identifies the microorganisms responsible for blood infections that may lead to sepsis. We are the first to build a purpose-designed genomic analysis platform to complete the entire diagnostic process, from raw sample input to clinically actionable output, within 2 to 3 hours.
Genomic research has enabled a whole new wave of diagnostic testing based on DNA markers of diseases. Diseases characterized by small numbers of simple markers can be identified using relatively simple molecular diagnostic techniques such as real-time PCR, or genotyping. More complex conditions, involving multiple and/or complex markers require more comprehensive approaches such as Next Generation Sequencing (NGS).
However, current commercial NGS technology is still at the mainframe stage of evolution and firmly entrenched in the central research laboratory.
Genalysis® changes the rules of molecular diagnostics, by combining the best characteristics of PCR, genotyping and NGS on a single semiconductor chip that works directly at the point of need.
Fast tests save lives by allowing the most effective therapy to be identified and administered at the earliest stage of an infection. Appropriate treatment can begin swiftly, safeguarding the life of the patient and reducing the time spent in hospital.
Genalysis® testing will soon transform healthcare by providing lab-accurate diagnostics at the point of need. This has far-reaching and positive implications for personalized healthcare, infection screening and more. MORE
Our first product will diagnose bloodstream infections within 2 to 3 hours, identifying the infectious agent(s), so that the appropriate antibiotics can be given to the patient in time to stop any acceleration of the disease. MORE
Dec 2 2016
DNAe Congratulates Executive Chairman Professor Chris Toumazou on Elektra European Electronics Industry Lifetime Achievement Award
Nov 9 2016
DNAe to Present New Data on G-BSI Blood-to-Result Test for Rapid Identification of Bloodstream Infections at AMP 2016
Sept 30 2016
BARDA Awards $51.9 Million Contract to DNAe to Develop Semiconductor DNA Sequencing Platform for Rapid Diagnosis of Antimicrobial Resistant Infections and Influenza
Dec 4 2015
DNAe Expands US Operations with Clinical Diagnostic Development and Manufacturing Site in San Diego
Nov 2 2015
DNAe Secures £25 million ($38 million) Bank Facility to Fund Development of Pioneering Point-of-Need IVD for Serious Blood Infections
© 2016 DNA Electronics